- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NPPA sets retail prices for 41 drugs, including 29 Fixed-Dose Combinations containing Empagliflozin or Sitagliptin

New Delhi: In its 133rd meeting held on May 29, 2025, the National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 41 drug formulations under the Drugs (Prices Control) Order, 2013.
Among these, 29 of these formulations are anti-diabetic fixed-dose combinations (FDCs) involving the widely prescribed agents Empagliflozin and Sitagliptin. These include:
. 18 Empagliflozin-based combinations, with prices ranging from Rs 9.90 to Rs 33.13 per tablet.
. 11 Sitagliptin-based combinations (with Glimepiride and Metformin), all priced between Rs 12.82 and Rs 14.50 per tablet.
The price control move targets widely prescribed anti-diabetic fixed-dose combinations, manufactured and marketed by companies including Zydus Healthcare, USV, Emcure Pharma, Alkem Labs, Glenmark Pharma, and Torrent Pharma.
Apart from anti-diabetic combinations, NPPA also fixed retail prices for several other essential formulations, including Atorvastatin & Ezetimibe tablets for dyslipidemia, Ceftriaxone, Sulbactam & Disodium Edetate Powder for solution for Infusion for bacterial infections, Cholecalciferol oral drops for vitamin D deficiency, Melatonin & Zolpidem Tartrate tablets for sleep disorders, and Alginate Raft-Forming Oral Suspension for acid reflux. The move aims to ensure affordability of essential therapies across diverse therapeutic areas including cardiovascular, gastrointestinal, infectious diseases, and respiratory care. The retail prices are exclusive of GST.
Sl. No. | Medicines | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Alginate Raft- Forming Oral Suspension | Each 5 ml contains: Sodium Alginate IP 250 mg Sodium Bicarbonate IP 133.5 mg Calcium Carbonate IP 80 mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Apex Laboratories Pvt. Ltd. | 0.93 |
2 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Ezetimibe IP 10mg | 1 Tablet | M/s Safetab Life Science/ M/s Ajanta Pharma Ltd. | 19.66 |
3 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 80 mg Ezetimibe IP 10mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Zydus Healthcare Ltd. | 54.29 |
4 | Ceftriaxone, Sulbactam & Disodium Edetate Powder for solution for Infusion | Each vial contains: Ceftriaxone Sodium IP eq. to Ceftriaxone 1000 mg Disodium Edetate IP 37 mg Sulbactam Sodium IP eq. Sulbactam 500 mg | 1 vial | M/s BDR Pharma- ceuticals International Pvt. Ltd./ M/S Glenmark Pharma-ceuticals Ltd. | 515.57 |
5 | Cefuroxime & Potassium Clavulanate Tablets | Each film coated tablet contains: Cefuroxime Axetil IP eq. to Cefuroxime 500 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125 mg | 1 Tablet | M/s Supermax Drugs & Pharmaceuticals Pvt. Ltd./ M/s Profic Organic Ltd. | 60.62 |
6 | Cholecalciferol Oral Drops | Each ml of Suspension contains: Vitamin D3 IP 800 IU | 1 ml | M/s Stedman Pharmaceuticals Pvt. Ltd. | 4.76 |
7 | Clindamycin & Nicotinamide gel | Clindamycin Phosphate IP eq. to Clindamycin 1.00% w/w Nicotinamide IP 4.00% w/w | 1 gm | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 7.24 |
8 | Iron, Folic Acid & Cyanocobalamin Syrup | Each 5 ml contains: Ferric Ammonium Citrate IP 110 mg Folic Acid IP 1.5 mg Cyanocobalamin IP 15 mcg Sorbitol (70%) (Non- Crystallising) | 1 ml | M/s East African (I) Overseas / M/s Mankind Prime Labs Pvt. Ltd. | 0.23 |
9 | Melatonin & Zolpidem Tartrate Tablets | Each film coated tablet contains: Melatonin BP 3 mg Zolpidem Tartrate IP 5 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Ipca Laboratories Ltd. | 6.62 |
10 | Melatonin & Zolpidem Tartrate Tablets | Each film coated tablet contains: Melatonin BP 3 mg Zolpidem Tartrate IP 10 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Ipca Laboratories Ltd. | 8.73 |
11 | Polmacoxib & Paracetamol Tablets | Each uncoated tablet contains: Polmacoxib IH 2 mg Paracetamol IP 325 mg | 1 Tablet | M/s Hetero Labs Ltd./ M/s Zuventus Healthcare Ltd. | 15.39 |
12 | Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Empagliflozin 10mg Metformin Hydrochloride 1000mg (as extended release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd. | 9.90 |
13 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 18.10 |
14 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Zydus Healthcare Ltd. | 18.10 |
15 | Empagliflozin & Metformin Hydrochloride Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 19.01 |
16 | Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 12.5 mg Metformin Hydrochloride IP 1000 mg (as Extended release) | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. | 17.86 |
17 | Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as extended release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Blue Cross Laboratories Pvt. Ltd. | 11.70 |
18 | Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg Metformin Hydrochloride IP 1000 mg (as Extended release) | 1 Tablet | M/s MSN Laboratories Pvt. Ltd. | 18.75 |
19 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 10 mg Linagliptin 5 mg Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 29.08 |
20 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 10 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 29.08 |
21 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 10 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Glenmark Pharmaceuticals Ltd. | 29.08 |
22 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 10 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd. | 28.57 |
23 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 10 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd. | 17.50 |
24 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Zydus Healthcare Ltd. | 33.13 |
25 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Cadila Pharmaceuticals Ltd. | 32.43 |
26 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd. | 33.13 |
27 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Glenmark Pharmaceuticals Ltd. | 33.13 |
28 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Laboratories Ltd. | 30.36 |
29 | Empagliflozin, Linagliptin & Metformin Hydrochloride (ER) Tablets | Each film coated tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Torrent Pharmaceuticals Ltd. | 19.50 |
30 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s USV Private Ltd. | 12.82 |
31 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd. | 12.82 |
32 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Alkem Laboratories Ltd. | 12.82 |
33 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Dr. Reddys Laboratories Ltd. | 12.82 |
34 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Zydus Healthcare Ltd. | 12.82 |
35 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s USV Private Ltd. | 14.50 |
36 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Emcure Pharmaceuticals Ltd. | 14.50 |
37 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Alkem Laboratories Ltd. | 14.50 |
38 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Eris Lifesciences Ltd. | 14.50 |
39 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Dr. Reddys Laboratories Ltd. | 14.50 |
40 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Zydus Healthcare Ltd. | 14.50 |
41 | Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup | Each 5 ml contains: Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s Vapi Care Pharma Pvt. Ltd. / M/s Apex Laboratories Pvt. Ltd. | 1.01 |
Note:
For complete product-wise details, refer to official notification.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751